Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases
October 21, 2021Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel VittWorld Journal of Gastrointestinal PathophysiologyPublished: December 12, 2020https://doi.org/10.4291/wjgp.v11.i6.114IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
October 21, 2021Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus…Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity Against Mammarenaviruses In Vitro
October 21, 2021Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la TorreVirusesPublished: July 29,…Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis
October 21, 2021Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel VittMultiple Sclerosis and Related DisordersPublished: May 6, 2020https://doi.org/10.1016/j.msard.2020.102129Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects
October 21, 2021Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel VittEuropean Journal of Drug Metabolism and PharmacokineticsPublished: May 2, 2020https://doi.org/10.1007/s13318-020-00623-7The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study
October 21, 2021Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel VittDrugs in R&DPublished: October 16, 2019https://doi.org/10.1007/s40268-019-00286-z
